AR050251A1 - Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto - Google Patents
Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuestoInfo
- Publication number
- AR050251A1 AR050251A1 ARP050102198A ARP050102198A AR050251A1 AR 050251 A1 AR050251 A1 AR 050251A1 AR P050102198 A ARP050102198 A AR P050102198A AR P050102198 A ARP050102198 A AR P050102198A AR 050251 A1 AR050251 A1 AR 050251A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- carbonyl
- amino
- heterocyclyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Estos compuestos pueden utilizarse para preparar medicamentos, en particular como inhibidores de sintasa de aldosterona. Pueden ser empleados para la prevencion a retardo del avance del estado de hipocalcemia, hipertension, insuficiencia cardíaca congestiva, insuficiencia renal aguda, restinitis y ateroesclerosis, entre otras. Reivindicacion1: Compuestos de la formula general 1 en la cual X es C; Y es C, si Z es C, es también N; Z es C o un enlace; R es hidrogeno, alquilo C1-8, alcoxi C1- 8-alquiloC0-4, halogeno o trifluormetilo; R1 es heterociclilo no saturado-alquilo C0-4, radical que está sin substituir o substituido con 1-4 alquilo C1-8-sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquilo C0-8-carbonil-alquil C1-8-amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8, alcoxi C1-8-carbonilo, heterociclilo o arilo, en donde heterociclilo o arilo están sin substituir o substituidos con 1-4 alquilo C1_8, alquil C1-8-sulfonilo, halogeno, cioano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8.carbonil-amino, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8-amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, caboxi-alquilo C0-4, alcoxilo C1-8-carbonilo; R2 a) es hidrogeno; o b) es alquilo C1-8, cicloalquilo C3-8, halogeno, carboxi-alquilo C1-4, alcoxi C1-4-carbonil-alquilo C1-4, alquil C0-4-carbonilo, aril-alquilo C0-4 o heterociclilo no saturado-alquilo C0-4, radicales que están sin substituir o substituidos con 1-4 alquilo C1-8, alquil C0-8-carbonilo, alquil C1-8 -sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8-amino, cabamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8, alcoxi C1-8-carbonilo, heterociclilo, arilo, en donde heterociclilo o arilo están sin substituir o substituidos con 1-4 alquilo C1-8, alquil C0-8-carbonilo, alquilo C1-8-sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8- amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8 o alcoxi C1-8-carbonilo; n es un numero 0, 1 o 2; y las sales de los mismos, preferentemente las sales faramcéuticamente utiles de los mismos, y su sal, pro droga o compuesto en el cual uno o másátomos están reemplazados por sus isotopos no radioactivos estables, en particular, sal farmacéuticamente util; en los caules si Z es un enlace y R2 es hidrogeno, R1 no es carbazol, benzoimidoazolilo, benzotriazolilo, priridilo, pirimidinilo, pirazinilo o piridazinilo, o si Z es un enlace, R2 es hidrogeno y R1 es un radical heterocíclico que contiene S no saturado, monocíclico, estando estos radicales substituidos con alquil C0-8-carbonilo, ciano, arilo o heterociclilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH9162004 | 2004-05-28 | ||
| CH11572004 | 2004-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050251A1 true AR050251A1 (es) | 2006-10-11 |
Family
ID=34993240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102198A AR050251A1 (es) | 2004-05-28 | 2005-05-27 | Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080076794A1 (es) |
| EP (1) | EP1748986B1 (es) |
| JP (1) | JP2008500999A (es) |
| AR (1) | AR050251A1 (es) |
| AT (1) | ATE490241T1 (es) |
| BR (1) | BRPI0510412A (es) |
| CA (1) | CA2568164A1 (es) |
| DE (1) | DE602005025110D1 (es) |
| IL (1) | IL179409A0 (es) |
| TW (1) | TW200608978A (es) |
| WO (1) | WO2005118541A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8680079B2 (en) * | 2004-05-28 | 2014-03-25 | Novartis Ag | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors |
| TW200716105A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| UY32660A (es) | 2009-05-28 | 2010-12-31 | Novartis Ag | Derivados aminobutricos sustituidos como inhibidores de neprilisina |
| AU2010251967B9 (en) | 2009-05-28 | 2014-04-03 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| AU2014216424B2 (en) | 2013-02-14 | 2016-05-05 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors |
| AP2016009019A0 (en) | 2013-07-25 | 2016-02-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| AP2016009021A0 (en) | 2013-07-25 | 2016-02-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| WO2016116842A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| CN113166101A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物 |
| WO2020110011A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859691A (en) * | 1987-07-08 | 1989-08-22 | Ciba-Geigy Corporation | Certain 1,2-benzisoxazole derivatives |
| GB8820730D0 (en) * | 1988-09-02 | 1988-10-05 | Erba Carlo Spa | Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation |
| US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
| JP3170273B2 (ja) * | 1989-06-05 | 2001-05-28 | 第一製薬株式会社 | 縮合トリアジン誘導体及びその中間体 |
| IL94592A (en) * | 1989-06-05 | 1994-07-31 | Daiichi Seiyaku Co | History Transformed by piperidinoalkyl of 1,2,4-triazolone and 1,3,5-triazinedione in compressed bicycles, their preparation and pharmaceutical preparations containing or |
| CA2026792A1 (en) * | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
| KR100263412B1 (ko) * | 1992-01-27 | 2000-08-01 | 디르크 반테 | 아로마타제 억제제로서 피롤로이미다졸릴 및 이미다조피리디닐 치환된 1h-벤즈이미다졸 유도체 |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| EP1311192A4 (en) * | 1999-10-22 | 2006-03-01 | Glaxo Group Ltd | -G- (IN VIVO) IMAGING |
| US20030083342A1 (en) * | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
-
2005
- 2005-05-27 TW TW094117479A patent/TW200608978A/zh unknown
- 2005-05-27 US US11/597,615 patent/US20080076794A1/en not_active Abandoned
- 2005-05-27 AR ARP050102198A patent/AR050251A1/es unknown
- 2005-05-27 AT AT05749325T patent/ATE490241T1/de not_active IP Right Cessation
- 2005-05-27 JP JP2007513941A patent/JP2008500999A/ja active Pending
- 2005-05-27 BR BRPI0510412-2A patent/BRPI0510412A/pt not_active IP Right Cessation
- 2005-05-27 EP EP05749325A patent/EP1748986B1/en not_active Not-in-force
- 2005-05-27 CA CA002568164A patent/CA2568164A1/en not_active Abandoned
- 2005-05-27 WO PCT/EP2005/052418 patent/WO2005118541A2/en not_active Application Discontinuation
- 2005-05-27 DE DE602005025110T patent/DE602005025110D1/de not_active Expired - Fee Related
-
2006
- 2006-11-20 IL IL179409A patent/IL179409A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1748986B1 (en) | 2010-12-01 |
| US20080076794A1 (en) | 2008-03-27 |
| WO2005118541A3 (en) | 2006-02-02 |
| CA2568164A1 (en) | 2005-12-15 |
| IL179409A0 (en) | 2007-05-15 |
| JP2008500999A (ja) | 2008-01-17 |
| ATE490241T1 (de) | 2010-12-15 |
| TW200608978A (en) | 2006-03-16 |
| BRPI0510412A (pt) | 2007-10-23 |
| EP1748986A2 (en) | 2007-02-07 |
| DE602005025110D1 (de) | 2011-01-13 |
| WO2005118541A2 (en) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050251A1 (es) | Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto | |
| AR047706A1 (es) | Inhibidores de polimerasa viral | |
| AR065901A1 (es) | Derivados de pirrolipirimidina | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
| AR040076A1 (es) | Derivados de piridazin-3(2h)-ona | |
| AR058006A1 (es) | Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR059778A1 (es) | Compuestos de pirrolotriazina inhibidores de quinasas p38,composiciones farmaceuticas que los contienen y usos en gran variedad de procesos inflamatorios. | |
| PE20190337A1 (es) | NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| AR035783A1 (es) | Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3 | |
| AR066691A1 (es) | Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas. | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR071609A1 (es) | Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1 | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
| AR067271A1 (es) | Derivados de triazolona inhibidores no nucleosidos de la transcriptasa inversa, utiles para el tratamiento de enfermedades mediadas por el vih o el arc y composiciones farmaceuticas que los contienen. | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| AR078270A1 (es) | Inhibidores de jak (quinasas janus) | |
| AR056645A1 (es) | Compuestos de urea sustituida inhibidores de enzimas chk1 . | |
| NI201000011A (es) | Derivados de pirimidina 934. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |